Amarin (AMRN) and The Competition Head to Head Contrast

Amarin (NASDAQ:AMRN) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Amarin to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, earnings, dividends, profitability and valuation.

Profitability

This table compares Amarin and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-10.87%	-0.52%	-0.36%
Amarin Competitors	-2,380.91%	-221.73%	-15.99%

Risk and Volatility

Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Amarin’s competitors have a beta of -4.22, indicating that their average share price is 522% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Amarin and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2	0	0	1	2.00
Amarin Competitors	7764	13847	25695	1031	2.41

Amarin currently has a consensus price target of $13.00, suggesting a potential upside of 7.71%. As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given Amarin’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Amarin has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Amarin and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amarin	$176.11 million	-$38.80 million	-12.57
Amarin Competitors	$4.64 billion	$3.23 billion	545.49

Amarin’s competitors have higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

22.3% of Amarin shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Amarin competitors beat Amarin on 8 of the 13 factors compared.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.